Finance

Lists
1099:HKG
Sinopharm Group Co Ltd
15,72 HKD
+0,45%
(+0,070) 1D
16 ოქტ, 16:08:14 GMT+8  ·   HKD
All symbols
SymbolPriceChange% Change
Generating top insights for 1099...
Open
15,79 HKD
High
15,99 HKD
Low
15,67 HKD
Mkt. cap
49,06 მლრდ.
Avg. vol.
4,85 მლნ.
Volume
5,89 მლნ.
Dividend
5,03%
Quarterly dividend
0,20 HKD
Ex-dividend date
23 ივნ. 2026
P/E ratio
5,90
52-wk high
22,34 HKD
52-wk low
14,55 HKD
EPS
2,67 HKD
Shares outstanding
1,19 მლრდ.
No. of employees
90 ათ.
Open
15,79 HKD
High
15,99 HKD
Low
15,67 HKD
Mkt. cap
49,06 მლრდ.
Avg. vol.
4,85 მლნ.
Volume
5,89 მლნ.
Dividend
5,03%
Quarterly dividend
0,20 HKD
Ex-dividend date
23 ივნ. 2026
P/E ratio
5,90
52-wk high
22,34 HKD
52-wk low
14,55 HKD
EPS
2,67 HKD
Shares outstanding
1,19 მლრდ.
No. of employees
90 ათ.
News stories
From web sources and news partners
Profile
Sinopharm Group Co., Ltd. is a Chinese pharmaceutical company. The parent company of Sinopharm Group was Sinopharm Industrial Investment, a 51–49 joint venture of state-owned enterprise China National Pharmaceutical Group and civilian-run enterprise Fosun Pharmaceutical. Its H shares were listed on the Hong Kong Stock Exchange in 2009, with its IPO price of HK$16 per share. Sinopharm Group's subsidiary Sinopharm CNMC and Sinopharm Accord served as the A share counterpart of the company. However, the A share of Sinopharm Group itself was unlisted. Sinopharm Group was ranked 829th in 2016 Forbes Global 2000 list. Wikipedia
About Sinopharm Group Co Ltd
CEO-
Employees90,4 ათ.
Founded2003
Headquarters-
SectorHealth care provider
Last report
24 აგვ. 2026
Fiscal period
Q2 2026
- / -
Revenue / Est. (CNY)
142,03 მლრ. / -
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
145,44 მლრ.
143,69 მლრ.
140,77 მლრ.
142,03 მლრ.
Cost of goods sold
134,52 მლრ.
133,28 მლრ.
131,40 მლრ.
132,33 მლრ.
Cost of revenue
134,52 მლრ.
133,28 მლრ.
131,40 მლრ.
132,33 მლრ.
Research and development expenses
172,61 მლნ.
-172,61 მლნ.
46,59 მლნ.
-46,59 მლნ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5,17 მლრდ.
7,34 მლრდ.
5,10 მლრდ.
5,70 მლრდ.
Operating expense
6,80 მლრდ.
5,00 მლრდ.
6,29 მლრდ.
5,45 მლრდ.
Total operating expenses
141,32 მლრ.
138,29 მლრ.
137,69 მლრ.
137,78 მლრ.
Operating income
4,12 მლრდ.
5,40 მლრდ.
3,07 მლრდ.
4,26 მლრდ.
Other non operating income
120,78 მლნ.
-427,44 მლნ.
39,60 მლნ.
-100,78 მლნ.
EBT including unusual items
3,67 მლრდ.
3,92 მლრდ.
2,90 მლრდ.
4,05 მლრდ.
EBT excluding unusual items
3,51 მლრდ.
5,36 მლრდ.
2,90 მლრდ.
4,25 მლრდ.
Income tax expense
905,42 მლნ.
1,19 მლრდ.
712,28 მლნ.
1,05 მლრდ.
Effective tax rate
24,66%
30,30%
24,57%
26,02%
Other operating expenses
917,07 მლნ.
-1,10 მლრდ.
204,49 მლნ.
-392,73 მლნ.
Net income
1,84 მლრდ.
1,85 მლრდ.
1,41 მლრდ.
1,99 მლრდ.
Net profit margin
1,27%
1,29%
1,00%
1,40%
Earnings per share
-
-
-
-
Interest and investment income
364,24 მლნ.
-
171,27 მლნ.
-
Interest expense
-412,56 მლნ.
-846,59 მლნ.
-383,82 მლნ.
-505,78 მლნ.
Net interest expenses
-48,32 მლნ.
-846,59 მლნ.
-212,55 მლნ.
-505,78 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
4,66 მლრდ.
5,91 მლრდ.
3,58 მლრდ.
4,78 მლრდ.
Gain or loss from assets sale
11,79 მლნ.
-20,53 მლნ.
-
-14,32 მლნ.
AI content may include mistakes. Learn more
Google აპები